SCHEMBL24089504

SCHEMBL24089504

Cc1ccc2c(c(C3CC3)nn2CC(C)(C)c2c(C)ccc3cnn(C)c23)c1C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24089579 0.89 — —
SCHEMBL24089391 0.75 HDAC4 (0.31) —
SCHEMBL22328036 0.71 ALDH1A1 (0.30) —
SCHEMBL22924139 0.67 — —
SCHEMBL22924128 0.66 — —
SCHEMBL22924152 0.66 — —
SCHEMBL22924125 0.66 — —
SCHEMBL29300347 0.63 — —
SCHEMBL18408663 0.61 MAPT (0.34) —
SCHEMBL22328033 0.61 EZH2 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380595-A1 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS ARAXES PHARMA LLC (US) 2021-12-09 — — US disclosed
Send feedback